Chugai Pharma USA, Inc.

Chugai Pharma USA, Inc.
Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients.


Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai originated innovative new drug candidates.


Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. Chugai has recently established Translational Clinical Research Division (TCRD) as its first global organization, composed of TCR functions in Japan, Europe, and U.S. (CPUSA). The division specializes in early clinical development of Chugai origin pipeline products, and aims to accelerate PoC for rapid shift to global development.
(908) 516-1350
300 Connell Drive, Suite 3100,
Berkeley Heights, NJ 07922
http://www.sci.bio/job-search/

Send Message to listing owner

Chugai Pharma USA, Inc.